BioNexus Gene Lab (NASDAQ:BGLC) versus NewGenIvf Group (NASDAQ:NIVF) Head to Head Survey

BioNexus Gene Lab (NASDAQ:BGLC) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are held by institutional investors. 0.7% of BioNexus Gene Lab shares are held by company insiders. Comparatively, 31.8% of NewGenIvf Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

BioNexus Gene Lab has a beta of 5.24, meaning that its stock price is 424% more volatile than the S&P 500. Comparatively, NewGenIvf Group has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for BioNexus Gene Lab and NewGenIvf Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1	0	0	0	1.00
NewGenIvf Group	1	0	0	0	1.00

Profitability

This table compares BioNexus Gene Lab and NewGenIvf Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-24.26%	-30.18%	-24.85%
NewGenIvf Group	N/A	N/A	N/A

Valuation & Earnings

This table compares BioNexus Gene Lab and NewGenIvf Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$9.51 million	0.83	-$1.60 million	($0.76)	-5.79
NewGenIvf Group	$5.43 million	0.14	-$520,000.00	N/A	N/A

NewGenIvf Group has lower revenue, but higher earnings than BioNexus Gene Lab.

Summary

NewGenIvf Group beats BioNexus Gene Lab on 6 of the 9 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.